On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...

Professor Michel Sadelain, of Canadian origins, was announced the 2025 laureate for King Faisal Prize in Medicine for his groundbreaking contributions to Chimeric Antigen Receptor (CAR) T-cell therapy ...

Caribou Biosciences (NASDAQ:CRBU – Get Free Report) had its price target dropped by equities researchers at Bank of America from $13.00 to $11.00 in a research report issued to clients and investors ...

Astellas has ended work on a cell therapy that it was exploring for CD20-positive B cell lymphomas, the Japan-based pharma ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...